Listen to Prof. Michael Gibson discuss the risks associated with early and late recurrent events in patients with recent ACS, and the implications this could have on trial design.
Listen to Prof Michael Gibson as he explores the association between cholesterol efflux and adverse CV events. He also discusses the potential of cholesterol efflux as a novel therapeutic target to improve outcomes for patients with CV disease.
Listen to Dr. Keith Allen discuss the impact of recurrent CV events in the high-risk 90-day period post AMI.
Listen to Dr Anand Rohatgi describe the process of cholesterol efflux and the data that demonstrate the importance of cholesterol efflux in determining cardiovascular outcomes.
Find out about the significant healthcare costs associated with recurrent CV events post AMI1-4
Current standard of care and newer therapies have lowered the long-term risk of recurrent CV events; however, data show that patients are still at risk during the 90-day high-risk period after an AMI5-12
Learn about the role of cholesterol efflux in removing excess cholesterol from lipid-laden macrophages in arterial plaque13,14
Sign up to receive news alerts and information about educational resources to help your patients through the 90-day high-risk period post AMI
By submitting this form, you are consenting to disclose any information provided, including your name, email address, telephone number, and any other information (collectively “Personal Information”) to CSL Behring and its representatives, agents, and contractors, including CSL Behring’s support program(s) (collectively “CSL Behring Entities”) and to receive communications with relevant information from CSL Behring Entities. You may be contacted by mail, email, telephone, and/or SMS/text message in relation to our business, products, services, and educational programs intended to benefit patients using or eligible to use CSL Behring therapies. You will have the ability to opt-out from receiving communications from CSL Behring Entities at any time. CSL Behring and CSL Behring Entities will not sell your personal information. CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy
ACC, American College of Cardiology; AHA, American Heart Association; ACS, acute coronary syndrome; AMI, acute myocardial infarction; ApoA-I, apolipoprotein A-I; ASCVD, atherosclerotic cardiovascular disease; CV, cardiovascular; ESC, European Society of Cardiology; HDL, high-density lipoprotein; LDL, low-density lipoprotein
1. Bakhai A et al. J Interv Cardiol 2012; 25:19–27.
2. Punekar RS et al. Clin Cardiol 2015; 38:483–491.
3. Zhao Z, Winget M. BMC Health Serv Res 2011; 11:35.
4. Chapman RH et al. BMC Cardiovasc Disord 2011; 11:11.
5. Schwartz GG et al. N Engl J Med 2018; 379:2097–2107.
6. Cannon CP et al. N Engl J Med 2015; 372:2387–2397.
7. Schwartz GG et al. JAMA 2001; 285:1711–1718.
8. Bhatt DL et al. N Engl J Med 2019; 380:11–22.
9. Bhatt DL et al. J Am Coll Cardiol 2019; 73:2791–2802.
10. Mehta SR et al. N Engl J Med 2019; 381:1411–1421.
11. Wallentin L et al. N Engl J Med 2009; 361:1045–1057.
12. Nair R et al. J Am Heart Assoc 2021; 10:e019270.
13. Estrada-Luna D et al. Molecules 2018; 23:2730.
14. Silvain J et al. Curr Opin Cardiol 2019; 34:714–720.
USA-GEN-0051 | September 2022